These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 7654396

  • 1. Update: safety, new applications, new MR agents.
    Runge VM, Wells JW.
    Top Magn Reson Imaging; 1995; 7(3):181-95. PubMed ID: 7654396
    [Abstract] [Full Text] [Related]

  • 2. Magnetic resonance imaging contrast agents.
    Runge VM.
    Curr Opin Radiol; 1992 Feb; 4(1):3-12. PubMed ID: 1739599
    [Abstract] [Full Text] [Related]

  • 3. The use of MR contrast in nonneoplastic disease of the brain.
    Runge VM.
    Top Magn Reson Imaging; 1995 Feb; 7(3):158-67. PubMed ID: 7654394
    [Abstract] [Full Text] [Related]

  • 4. Magnetic resonance contrast agents in neuroimaging. New agents and applications.
    Runge VM, Kirsch JE, Wells JW, Dunworth JN, Awh MH, Bittner DF.
    Neuroimaging Clin N Am; 1994 Feb; 4(1):175-83. PubMed ID: 8130948
    [Abstract] [Full Text] [Related]

  • 5. Visualization of blood-brain barrier disruption on MR images of cats with acute cerebral infarction: value of administering a high dose of contrast material.
    Runge VM, Kirsch JE, Wells JW, Dunworth JN, Woolfolk CE.
    AJR Am J Roentgenol; 1994 Feb; 162(2):431-5. PubMed ID: 8310940
    [Abstract] [Full Text] [Related]

  • 6. Gadodiamide injection and gadopentetate dimeglumine. A double-blind study in MR imaging of the CNS.
    Myhr G, Rinck PA, Børseth A.
    Acta Radiol; 1992 Sep; 33(5):405-9. PubMed ID: 1389644
    [Abstract] [Full Text] [Related]

  • 7. Combination of gadolinium and dysprosium chelates as a cellular integrity marker in MR imaging.
    Ericsson A, Bach-Gansmo T, Niklasson F, Hemmingsson A.
    Acta Radiol; 1995 Jan; 36(1):41-6. PubMed ID: 7833167
    [Abstract] [Full Text] [Related]

  • 8. The use of MR contrast in neoplastic disease of the brain.
    Muroff LR, Runge VM.
    Top Magn Reson Imaging; 1995 Jan; 7(3):137-57. PubMed ID: 7654393
    [Abstract] [Full Text] [Related]

  • 9. Liver I: Currently available gadolinium chelates.
    Mitchell DG.
    Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):37-51. PubMed ID: 8673715
    [Abstract] [Full Text] [Related]

  • 10. Utility of magnetic resonance contrast agents in routine cranial imaging. Case study of an evaluative method.
    Wolf GL, Walsh SJ, McNeil BJ.
    Neuroimaging Clin N Am; 1994 Feb; 4(1):55-62. PubMed ID: 8130952
    [Abstract] [Full Text] [Related]

  • 11. [Contrast-enhanced MR imaging using double doses of gadolinium-DTPA in evaluating brain and spinal diseases].
    Matsumoto S, Hasuo K, Uchino A, Matsuura Y, Gibo M, Fukui M, Masuda K.
    Nihon Igaku Hoshasen Gakkai Zasshi; 1993 May 25; 53(5):503-10. PubMed ID: 8327315
    [Abstract] [Full Text] [Related]

  • 12. [Use of Omniscan (gadodiamide) in magnetic resonance studies of the central nervous system (results of a multicenter study)].
    Sinitsyn VE, Kornienko VN, Nikitin VG, Pronin IN, Ternovoĭ SK, Tiutin LA, Iakobson MG.
    Vestn Rentgenol Radiol; 1995 May 25; (4):5-11. PubMed ID: 8571538
    [Abstract] [Full Text] [Related]

  • 13. Phase III clinical studies with gadoteridol for the evaluation of neurologic pathology. A European perspective.
    Seiderer M.
    Invest Radiol; 1992 Aug 25; 27 Suppl 1():S33-8. PubMed ID: 1506151
    [Abstract] [Full Text] [Related]

  • 14. [Gadolinium dimeglumine gadopentetate compared to CPMG sequencing and image synthesis].
    Higer HP, Just M, Grigat M, Meindl S, Jungke M, Bielke G, Pedrosa P, Kunze S, Voth D.
    Rofo; 1988 Mar 25; 148(3):307-13. PubMed ID: 2832897
    [Abstract] [Full Text] [Related]

  • 15. [Diagnosis of cerebral metastasis with standard dose gadobutrol vs. a high dose protocol. Intraindividual evaluation of a phase II high dose study].
    Vogl TJ, Friebe CE, Balzer T, Mack MG, Steiner S, Schedel H, Pegios W, Lanksch W, Banzer D, Felix R.
    Radiologe; 1995 Aug 25; 35(8):508-16. PubMed ID: 7568795
    [Abstract] [Full Text] [Related]

  • 16. MR contrast enhancement of intracranial lesions with Gd-DTPA.
    Hesselink JR, Press GA.
    Radiol Clin North Am; 1988 Jul 25; 26(4):873-87. PubMed ID: 3289078
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the safety of standard and triple dose gadodiamide injection in MR imaging of the central nervous system. A double-blind study.
    Svaland MG, Christensen T, Lundorf E.
    Acta Radiol; 1994 Jul 25; 35(4):396-9. PubMed ID: 8011392
    [Abstract] [Full Text] [Related]

  • 18. Intraindividual in vivo comparison of gadolinium contrast agents for pharmacokinetic analysis using dynamic contrast enhanced magnetic resonance imaging.
    Liang J, Sammet S, Yang X, Jia G, Takayama Y, Knopp MV.
    Invest Radiol; 2010 May 25; 45(5):233-44. PubMed ID: 20351653
    [Abstract] [Full Text] [Related]

  • 19. Non-T1-weighted spin-echo MR imaging with contrast material: experimental and preliminary clinical assessment.
    Mihara F, Gupta KL, Righi AM.
    Radiat Med; 1994 May 25; 12(5):209-12. PubMed ID: 7863024
    [Abstract] [Full Text] [Related]

  • 20. Magnetic resonance imaging contrast agents: theory and application to the central nervous system.
    Bronen RA, Sze G.
    J Neurosurg; 1990 Dec 25; 73(6):820-39. PubMed ID: 2230966
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.